64 studies found for:    Alkermes
Show Display Options
Rank Status Study
21 Completed ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
Condition: Binge Eating Disorder
Interventions: Drug: RDC-0313 (ALKS 33);   Drug: Placebo
22 Completed ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
Condition: Cocaine Abuse
Interventions: Drug: ALKS 33-BUP;   Drug: ALKS 33;   Drug: Placebo
23 Enrolling by invitation A Long-Term Safety Study of ALKS 5461
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
24 Completed A Study of ALKS 5461 in Healthy Volunteers
Condition: Pharmacokinetics
Interventions: Drug: ALKS 5461;   Drug: Placebo
25 Completed ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
Condition: Alcohol Dependence
Interventions: Drug: ALKS33 (RDC-0313) (1 mg);   Drug: ALKS33 (RDC-0313) (2.5 mg);   Drug: ALKS33 (RDC-0313) (10 mg);   Drug: Placebo
26 Completed Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Conditions: Diabetes Mellitus;   Asthma;   Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: injected insulin
27 Completed Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: Injectable Insulin;   Drug: Insulin Glargine
28 Completed Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: Injectable insulin
29 Completed Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: Insulin Glargine
30 Completed Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: Insulin Glargine
31 Completed Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: Injectable insulin;   Drug: Insulin Glargine
32 Completed Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder;   Drug: intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
33 Completed
Has Results
ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence
Condition: Alcohol Dependence
Interventions: Drug: VIVITROL 380 mg;   Drug: Placebo for VIVITROL 380 mg
34 Completed
Has Results
ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Oral naltrexone 50 mg
35 Completed
Has Results
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Placebo;   Drug: TrIP-2D;   Drug: TrIP-2SS;   Drug: TrIP-2SS + Foradil
36 Completed
Has Results
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
Condition: Opiate Dependence
Interventions: Drug: Medisorb naltrexone 75 mg;   Drug: Medisorb naltrexone 150 mg;   Drug: Medisorb naltrexone 300 mg;   Drug: Hydromorphone (10 mg/mL);   Drug: Naloxone Challenge and Oral Naltrexone Tolerability Testing
37 Completed
Has Results
ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 190 mg;   Drug: Medisorb naltrexone 380 mg;   Drug: Placebo matching Medisorb naltrexone 190 mg;   Drug: Placebo matching Medisorb naltrexone 380 mg
38 Active, not recruiting A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
Condition: Opioid Dependence
Intervention: Drug: VIVITROL 380mg
39 Completed ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry
Condition: Opioid Dependence
Intervention:
40 Terminated Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery
Condition: Laparoscopic Surgery
Interventions: Drug: N1539;   Drug: Ketorolac Tromethamine;   Drug: Placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years